Osimertinib (Figure 51) is a third-generation, irreversible EGFR-TKI that was approved by the FDA on November 13, 2015 for use in the treatment of EGFR T790M mutation-positive NSCLC [130]. Here, EGFR is linked to non-small cell lung carcinoma.